Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to $62.6 million.

  • Fulcrum Therapeutics' Shares Outstanding (Diluted Average) fell 171.3% to $62.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.6 million, marking a year-over-year decrease of 171.3%. This contributed to the annual value of $61984.0 for FY2024, which is 109.93% up from last year.
  • According to the latest figures from Q3 2025, Fulcrum Therapeutics' Shares Outstanding (Diluted Average) is $62.6 million, which was down 171.3% from $62.5 million recorded in Q2 2025.
  • Fulcrum Therapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $63.7 million for Q3 2024, and its period low was $32636.0 during Q2 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $61647.0 (2023), whereas its average is $27.8 million.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Shares Outstanding (Diluted Average) skyrocketed by 15102252.38% in 2023, and later plummeted by 179.01% in 2025.
  • Over the past 5 years, Fulcrum Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $35361.0 in 2021, then rose by 27.23% to $44991.0 in 2022, then skyrocketed by 36.27% to $61310.0 in 2023, then rose by 1.1% to $61984.0 in 2024, then soared by 100888.96% to $62.6 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $62.6 million for Q3 2025, versus $62.5 million for Q2 2025 and $62.5 million for Q1 2025.